Display options
Cite
Juntikka T, Vaittinen S, Vahlberg T, et al. Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. Front Oncol. 2021;11:710900doi: 10.3389/fonc.2021.710900.
Juntikka, T., Vaittinen, S., Vahlberg, T., Jyrkkiö, S., & Minn, H. (2021). Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. Frontiers in oncology, 11710900. https://doi.org/10.3389/fonc.2021.710900
Juntikka, Tiina, et al. "Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes." Frontiers in oncology vol. 11 (2021): 710900. doi: https://doi.org/10.3389/fonc.2021.710900
Juntikka T, Vaittinen S, Vahlberg T, Jyrkkiö S, Minn H. Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. Front Oncol. 2021 Jul 08;11:710900. doi: 10.3389/fonc.2021.710900. eCollection 2021. PMID: 34307181; PMCID: PMC8299948.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Jul 08;11:710900. doi: 10.3389/fonc.2021.710900. eCollection 2021.

Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes.

Frontiers in oncology

Tiina Juntikka, Samuli Vaittinen, Tero Vahlberg, Sirkku Jyrkkiö, Heikki Minn

Affiliations

  1. Department of Oncology and Radiotherapy, Turku University Hospital, University of Turku, Turku, Finland.
  2. Department of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
  3. Department of Clinical Medicine, Biostatistics, University of Turku, Turku, Finland.

PMID: 34307181 PMCID: PMC8299948 DOI: 10.3389/fonc.2021.710900

Abstract

BACKGROUND: Somatostatin receptors (SSTR) and chemokine receptor CXCR4 are expressed in lymphomas, while the abundance is known to be heterogeneous in different subtypes of lymphomas. Targeting tumor cells expressing these receptors might add to therapeutic opportunities while radiolabeled ligands for both imaging and therapy have been developed. The aim of this study was to establish SSTR subtype 2, 3 and 5 and also CXCR4 status immunohistochemically in six different lymphoma subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), mucosa-associated marginal B-cell lymphoma (MALT), Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL).

MATERIAL AND METHODS: This study included a total of 103 lymphoma patients (24 DLBCL, 22 FL, 18 HL, 9 MALT, 20 MCL and 10 PTCL) diagnosed in the Southwest hospital district of Finland during 2010-2019. SSTR 2, 3 and 5 and CXCR4 expression was analyzed immunohistochemically (IHC) in lymphoma samples obtained from local archival Biobank tissue repository. Immunopositivity of each receptor was scored on a four-point scale accounting for staining intensity and proportion of positively stained tumor cells.

RESULTS: Of different SSTR subtypes SSTR2 immunopositivity was most common and seen predominantly at the cell membrane of the malignant cells in 46-56% of DLBCL, HL and FL. CXCR4 co-expression was frequently present in these cases. SSTR3 and SSTR5 IHC were negative in DLBCL and FL but in HL SSTR expression was more heterogenous and SSTR3 and SSTR5 positivity was found in cytoplasm in 35% and 25% of cases. 2/4 blastoid MCL variants and one pleomorphic MCL variant had positive CXCR4 IHC whilst all other MCL cases (85%) were negative for all receptors. 30% (n=3) of the PTCL patients had positive SSTR5 IHC and CXCR4. MALT lymphomas were negative for all receptors.

CONCLUSION: SSTR2 and CXCR4 are found in DLBCL, FL and HL and co-expression of these receptors is common. Although in general expression of SSTRs and CXCR4 is heterogenous and very low in some subtypes such as MCL and MALT there are also patients with abundant expression. The latter are candidates for trials studying SSTR2 and/or CXCR4 based treatments in the future.

Copyright © 2021 Juntikka, Vaittinen, Vahlberg, Jyrkkiö and Minn.

Keywords: CXCR4; SSTR; chemokine receptor 4; immunohistochemistry; lymphoma; somatostatin receptor

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Leuk Lymphoma. 1997 Jun;26(1-2):107-14 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e781-6 - PubMed
  3. Ann Diagn Pathol. 2019 Aug;41:129-135 - PubMed
  4. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10 - PubMed
  5. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12 - PubMed
  6. Acta Haematol. 2019;142(2):64-70 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):468-475 - PubMed
  8. N Engl J Med. 2017 Jan 12;376(2):125-135 - PubMed
  9. Oncotarget. 2015 Mar 20;6(8):5597-614 - PubMed
  10. Histopathology. 2015 Sep;67(3):368-77 - PubMed
  11. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2083-2093 - PubMed
  12. Leuk Lymphoma. 2018 Jun;59(6):1451-1460 - PubMed
  13. Surgery. 2006 Dec;140(6):968-76; discussion 976-7 - PubMed
  14. Molecules. 2020 Dec 07;25(23): - PubMed
  15. Pathologe. 1987 May;8(3):138-40 - PubMed
  16. Int J Cancer. 1992 Apr 1;50(6):895-900 - PubMed
  17. Biomark Res. 2016 Jun 14;4:12 - PubMed
  18. Oncotarget. 2017 Jul 25;8(30):49123-49132 - PubMed
  19. Clin Cancer Res. 2013 Jul 1;19(13):3495-507 - PubMed
  20. J Pathol. 2015 Feb;235(3):445-55 - PubMed
  21. PET Clin. 2014 Jan;9(1):37-42 - PubMed
  22. Clin Nucl Med. 2014 Apr;39(4):358-9 - PubMed
  23. Oncotarget. 2019 Jan 22;10(7):717-731 - PubMed
  24. Semin Nucl Med. 1995 Jul;25(3):262-71 - PubMed
  25. J Cancer Res Clin Oncol. 2016 Nov;142(11):2239-47 - PubMed
  26. Am J Surg Pathol. 2019 Mar;43(3):374-381 - PubMed
  27. Blood. 2009 May 7;113(19):4604-13 - PubMed
  28. Acta Oncol. 2018 Feb;57(2):283-289 - PubMed
  29. J Nucl Med. 2004 Jan;45(1):8-16 - PubMed
  30. Semin Nucl Med. 2005 Jul;35(3):176-85 - PubMed

Publication Types